During the past decade, Cutting Edge Research Group conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 36 clinical trials were completed, i.e. on average, 128.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 19 clinical trials were completed. i.e. 633.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cutting Edge Research Group" #1 sponsor was "Sunovion" with 12 trials, followed by "Otsuka Pharmaceutical Development & Commercialization, Inc." with 8 trials sponsored, "Pfizer" with 8 trials sponsored, "Forest Laboratories" with 4 trials sponsored and "Hoffmann-La Roche" with 4 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cutting Edge Research Group" #1 collaborator was "H. Lundbeck A/S" with 3 trials as a collaborator, "Otsuka America Pharmaceutical" with 3 trials as a collaborator, "APCER Life Sciences" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Janssen, LP" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Cutting Edge Research Group" are "Major Depressive Disorder" (11 trials), "Alzheimer's Disease" (6 trials), "Attention Deficit Hyperactivity Disorder" (6 trials), "Schizophrenia" (6 trials) and "Bipolar Disorder" (5 trials). Many other conditions were trialed in "Cutting Edge Research Group" in a lesser frequency.

Most popular intervention types in "Cutting Edge Research Group" are "Drug" (59 trials), "Other" (4 trials), "Behavioral" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "Brexpiprazole" (4 trials), "Aripiprazole" (3 trials), "Dasotraline" (3 trials) and "Lurasidone" (3 trials). Other intervention names were less common.

The vast majority of trials in "Cutting Edge Research Group" are 60 trials for "All" genders.

Currently, there are NaN active trials in "Cutting Edge Research Group". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 45 completed trials in Cutting Edge Research Group, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Cutting Edge Research Group, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 42 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".